{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,12]],"date-time":"2026-11-12T03:09:11Z","timestamp":1794452951960,"version":"4.9.1"},"reference-count":115,"publisher":"Elsevier BV","issue":"5","license":[{"start":{"date-parts":[[2021,9,1]],"date-time":"2021-09-01T00:00:00Z","timestamp":1630454400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2021,9,1]],"date-time":"2021-09-01T00:00:00Z","timestamp":1630454400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"}],"funder":[{"DOI":"10.13039\/100000062","name":"National Institute of Diabetes and Digestive and Kidney Diseases","doi-asserted-by":"publisher","award":["1F32DK126331-01"],"award-info":[{"award-number":["1F32DK126331-01"]}],"id":[{"id":"10.13039\/100000062","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["ackdjournal.org","clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Advances in Chronic Kidney Disease"],"published-print":{"date-parts":[[2021,9]]},"DOI":"10.1053\/j.ackd.2021.10.008","type":"journal-article","created":{"date-parts":[[2022,2,18]],"date-time":"2022-02-18T12:06:27Z","timestamp":1645185987000},"page":"460-468.e1","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":58,"title":["Renal Cell Cancer and Chronic Kidney Disease"],"prefix":"10.1053","volume":"28","author":[{"ORCID":"https:\/\/orcid.org\/0000-0001-5807-6903","authenticated-orcid":false,"given":"Danielle L.","family":"Saly","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Meghana S.","family":"Eswarappa","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sarah E.","family":"Street","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Priya","family":"Deshpande","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"issue":"1","key":"10.1053\/j.ackd.2021.10.008_bib1","first-page":"7","article-title":"Cancer statistics, 2020","volume":"70","author":"Siegel","year":"2020","journal-title":"CA Cancer J Clin"},{"issue":"1-6","key":"10.1053\/j.ackd.2021.10.008_bib2","doi-asserted-by":"crossref","first-page":"461","DOI":"10.3233\/CBM-2011-0176","article-title":"Renal cell carcinoma","volume":"9","author":"Cairns","year":"2010","journal-title":"Cancer Biomark"},{"issue":"3","key":"10.1053\/j.ackd.2021.10.008_bib3","doi-asserted-by":"crossref","first-page":"471","DOI":"10.1016\/j.kint.2018.01.023","article-title":"Renal cell carcinoma for the nephrologist","volume":"94","author":"Perazella","year":"2018","journal-title":"Kidney Int"},{"issue":"7912","key":"10.1053\/j.ackd.2021.10.008_bib4","doi-asserted-by":"crossref","first-page":"883","DOI":"10.1016\/S0140-6736(75)91684-0","article-title":"Increased incidence of malignancy during chronic renal failure","volume":"1","author":"Matas","year":"1975","journal-title":"Lancet"},{"issue":"4","key":"10.1053\/j.ackd.2021.10.008_bib5","first-page":"719","article-title":"A summary of the status of de novo cancer in transplant recipients","volume":"4","author":"Penn","year":"1972","journal-title":"Transplant Proc"},{"issue":"2","key":"10.1053\/j.ackd.2021.10.008_bib6","doi-asserted-by":"crossref","first-page":"135","DOI":"10.1111\/j.1365-2559.1993.tb00091.x","article-title":"High incidence of papillary renal cell tumours in patients on chronic haemodialysis","volume":"22","author":"Ishikawa","year":"1993","journal-title":"Histopathology"},{"issue":"9218","key":"10.1053\/j.ackd.2021.10.008_bib7","doi-asserted-by":"crossref","first-page":"1886","DOI":"10.1016\/S0140-6736(00)02298-4","article-title":"Cancer risk in patients on dialysis and after renal transplantation","volume":"355","author":"Birkeland","year":"2000","journal-title":"Lancet"},{"issue":"9173","key":"10.1053\/j.ackd.2021.10.008_bib8","doi-asserted-by":"crossref","first-page":"93","DOI":"10.1016\/S0140-6736(99)06154-1","article-title":"Cancer in patients on dialysis for end-stage renal disease: an international collaborative study","volume":"354","author":"Maisonneuve","year":"1999","journal-title":"Lancet"},{"issue":"2","key":"10.1053\/j.ackd.2021.10.008_bib9","doi-asserted-by":"crossref","first-page":"119","DOI":"10.1016\/S0272-6386(89)80187-8","article-title":"Neoplasms in dialysis patients: a population-based study","volume":"14","author":"Port","year":"1989","journal-title":"Am J Kidney Dis"},{"issue":"11","key":"10.1053\/j.ackd.2021.10.008_bib10","doi-asserted-by":"crossref","first-page":"2461","DOI":"10.1681\/ASN.V7112461","article-title":"Renal cell carcinoma of end-stage renal disease: a histopathologic and molecular genetic study","volume":"7","author":"Hughson","year":"1996","journal-title":"J Am Soc Nephrol"},{"issue":"5","key":"10.1053\/j.ackd.2021.10.008_bib11","doi-asserted-by":"crossref","first-page":"1146","DOI":"10.1016\/S0022-5347(17)36329-2","article-title":"Re: acquired cystic disease of the kidney: a management dilemma","volume":"149","author":"Ishikawa","year":"1993","journal-title":"J Urol"},{"issue":"12","key":"10.1053\/j.ackd.2021.10.008_bib12","doi-asserted-by":"crossref","first-page":"1669","DOI":"10.1097\/00007890-199812270-00017","article-title":"Prospective pretransplant ultrasound screening in 206 patients for acquired renal cysts and renal cell carcinoma","volume":"66","author":"Gulanikar","year":"1998","journal-title":"Transplantation"},{"issue":"1","key":"10.1053\/j.ackd.2021.10.008_bib13","doi-asserted-by":"crossref","first-page":"197","DOI":"10.1097\/01.ASN.0000039608.81046.81","article-title":"Cancers of the kidney and urinary tract in patients on dialysis for end-stage renal disease: analysis of data from the United States, Europe, and Australia and New Zealand","volume":"14","author":"Stewart","year":"2003","journal-title":"J Am Soc Nephrol"},{"issue":"6","key":"10.1053\/j.ackd.2021.10.008_bib14","doi-asserted-by":"crossref","first-page":"1452","DOI":"10.1002\/ijc.28144","article-title":"Association of cancer with moderately impaired renal function at baseline in a large, representative, population-based cohort followed for up to 30 years","volume":"133","author":"Christensson","year":"2013","journal-title":"Int J Cancer"},{"issue":"10","key":"10.1053\/j.ackd.2021.10.008_bib15","doi-asserted-by":"crossref","first-page":"2327","DOI":"10.1681\/ASN.2013060604","article-title":"CKD and the risk of incident cancer","volume":"25","author":"Lowrance","year":"2014","journal-title":"J Am Soc Nephrol"},{"issue":"9","key":"10.1053\/j.ackd.2021.10.008_bib16","doi-asserted-by":"crossref","first-page":"1562","DOI":"10.1111\/jth.12650","article-title":"Diagnosis of suspected inherited platelet function disorders: results of a worldwide survey","volume":"12","author":"Gresele","year":"2014","journal-title":"J Thromb Haemost"},{"issue":"5","key":"10.1053\/j.ackd.2021.10.008_bib17","doi-asserted-by":"crossref","first-page":"1121","DOI":"10.2215\/CJN.09011010","article-title":"Cancer-specific mortality in chronic kidney disease: longitudinal follow-up of a large cohort","volume":"6","author":"Weng","year":"2011","journal-title":"Clin J Am Soc Nephrol"},{"issue":"1","key":"10.1053\/j.ackd.2021.10.008_bib18","doi-asserted-by":"crossref","first-page":"55","DOI":"10.1016\/j.kint.2021.03.011","article-title":"From kidney injury to kidney cancer","volume":"100","author":"Peired","year":"2021","journal-title":"Kidney Int"},{"issue":"6","key":"10.1053\/j.ackd.2021.10.008_bib19","doi-asserted-by":"crossref","first-page":"941","DOI":"10.1016\/S0090-4295(02)01825-3","article-title":"Molecular genetics and histopathologic features of adult distal nephron tumors","volume":"60","author":"Polascik","year":"2002","journal-title":"Urology"},{"issue":"536","key":"10.1053\/j.ackd.2021.10.008_bib20","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1126\/scitranslmed.aaw6003","article-title":"Acute kidney injury promotes development of papillary renal cell adenoma and carcinoma from renal progenitor cells","volume":"12","author":"Peired","year":"2020","journal-title":"Sci Transl Med"},{"issue":"5","key":"10.1053\/j.ackd.2021.10.008_bib21","doi-asserted-by":"crossref","first-page":"412","DOI":"10.1093\/ckj\/sfs091","article-title":"Solid renal tumours of collecting duct origin in patients on chronic lithium therapy","volume":"5","author":"Rookmaaker","year":"2012","journal-title":"Clin Kidney J"},{"issue":"3","key":"10.1053\/j.ackd.2021.10.008_bib22","doi-asserted-by":"crossref","first-page":"161","DOI":"10.1038\/nrneph.2015.8","article-title":"Sickle cell disease: renal manifestations and mechanisms","volume":"11","author":"Nath","year":"2015","journal-title":"Nat Rev Nephrol"},{"issue":"5","key":"10.1053\/j.ackd.2021.10.008_bib23","doi-asserted-by":"crossref","first-page":"535","DOI":"10.2116\/analsci.32.535","article-title":"Estimation using an enhancement factor on non local thermodynamic equilibrium behavior of high-lying energy levels of neutral atom in argon radio-frequency inductively-coupled plasma","volume":"32","author":"Wagatsuma","year":"2016","journal-title":"Anal Sci"},{"issue":"5","key":"10.1053\/j.ackd.2021.10.008_bib24","doi-asserted-by":"crossref","first-page":"1495","DOI":"10.1681\/ASN.2015040373","article-title":"Variation in cancer incidence among patients with ESRD during kidney function and Nonfunction Intervals","volume":"27","author":"Yanik","year":"2016","journal-title":"J Am Soc Nephrol"},{"issue":"1","key":"10.1053\/j.ackd.2021.10.008_bib25","doi-asserted-by":"crossref","first-page":"219","DOI":"10.1016\/j.juro.2011.03.032","article-title":"Renal cell carcinoma in the native and allograft kidneys of renal transplant recipients","volume":"186","author":"Leveridge","year":"2011","journal-title":"J Urol"},{"issue":"3","key":"10.1053\/j.ackd.2021.10.008_bib26","doi-asserted-by":"crossref","first-page":"20","DOI":"10.15586\/jkcvhl.2017.88","article-title":"A review of Von Hippel-Lindau syndrome","volume":"4","author":"Varshney","year":"2017","journal-title":"J Kidney Cancer VHL"},{"issue":"3 Pt 2","key":"10.1053\/j.ackd.2021.10.008_bib27","first-page":"907","article-title":"Hereditary papillary renal cell carcinoma: clinical studies in 10 families","volume":"153","author":"Zbar","year":"1995","journal-title":"J Urol"},{"issue":"8","key":"10.1053\/j.ackd.2021.10.008_bib28","doi-asserted-by":"crossref","first-page":"855","DOI":"10.2174\/1566524043359674","article-title":"Hereditary papillary renal carcinoma type I","volume":"4","author":"Dharmawardana","year":"2004","journal-title":"Curr Mol Med"},{"issue":"1","key":"10.1053\/j.ackd.2021.10.008_bib29","doi-asserted-by":"crossref","first-page":"95","DOI":"10.1086\/376435","article-title":"Mutations in the fumarate hydratase gene cause hereditary leiomyomatosis and renal cell cancer in families in North America","volume":"73","author":"Toro","year":"2003","journal-title":"Am J Hum Genet"},{"issue":"2","key":"10.1053\/j.ackd.2021.10.008_bib30","doi-asserted-by":"crossref","first-page":"157","DOI":"10.1016\/S1535-6108(02)00104-6","article-title":"Mutations in a novel gene lead to kidney tumors, lung wall defects, and benign tumors of the hair follicle in patients with the Birt-Hogg-Dube syndrome","volume":"2","author":"Nickerson","year":"2002","journal-title":"Cancer Cell"},{"issue":"9","key":"10.1053\/j.ackd.2021.10.008_bib31","doi-asserted-by":"crossref","first-page":"1061","DOI":"10.1158\/1541-7786.MCR-13-0111","article-title":"A novel germline mutation in BAP1 predisposes to familial clear-cell renal cell carcinoma","volume":"11","author":"Farley","year":"2013","journal-title":"Mol Cancer Res"},{"issue":"7456","key":"10.1053\/j.ackd.2021.10.008_bib32","doi-asserted-by":"crossref","first-page":"43","DOI":"10.1038\/nature12222","article-title":"Comprehensive molecular characterization of clear cell renal cell carcinoma","volume":"499","author":"Cancer Genome Atlas Research","year":"2013","journal-title":"Nature"},{"issue":"6","key":"10.1053\/j.ackd.2021.10.008_bib33","doi-asserted-by":"crossref","first-page":"1254","DOI":"10.1086\/301639","article-title":"Inherited mutations in PTEN that are associated with breast cancer, cowden disease, and juvenile polyposis","volume":"61","author":"Lynch","year":"1997","journal-title":"Am J Hum Genet"},{"issue":"17","key":"10.1053\/j.ackd.2021.10.008_bib34","doi-asserted-by":"crossref","first-page":"1260","DOI":"10.1093\/jnci\/djn254","article-title":"Germline SDHB mutations and familial renal cell carcinoma","volume":"100","author":"Ricketts","year":"2008","journal-title":"J Natl Cancer Inst"},{"issue":"1","key":"10.1053\/j.ackd.2021.10.008_bib35","doi-asserted-by":"crossref","first-page":"81","DOI":"10.1053\/j.ackd.2013.10.001","article-title":"Hereditary kidney cancer syndromes","volume":"21","author":"Haas","year":"2014","journal-title":"Adv Chronic Kidney Dis"},{"issue":"6","key":"10.1053\/j.ackd.2021.10.008_bib36","doi-asserted-by":"crossref","first-page":"1045","DOI":"10.1681\/ASN.V961045","article-title":"The genetics of renal tumors in end-stage renal failure differs from those occurring in the general population","volume":"9","author":"Chudek","year":"1998","journal-title":"J Am Soc Nephrol"},{"issue":"4","key":"10.1053\/j.ackd.2021.10.008_bib37","doi-asserted-by":"crossref","first-page":"282","DOI":"10.1016\/j.anndiagpath.2010.03.007","article-title":"Clear cell papillary renal cell carcinoma and clear cell renal cell carcinoma arising in acquired cystic disease of the kidney: an immunohistochemical and genetic study","volume":"15","author":"Kuroda","year":"2011","journal-title":"Ann Diagn Pathol"},{"issue":"2","key":"10.1053\/j.ackd.2021.10.008_bib38","doi-asserted-by":"crossref","first-page":"366","DOI":"10.1016\/j.eururo.2011.02.035","article-title":"Renal cell carcinoma (RCC) in patients with end-stage renal disease exhibits many favourable clinical, pathologic, and outcome features compared with RCC in the general population","volume":"60","author":"Neuzillet","year":"2011","journal-title":"Eur Urol"},{"issue":"3","key":"10.1053\/j.ackd.2021.10.008_bib39","doi-asserted-by":"crossref","first-page":"619","DOI":"10.1016\/j.brs.2021.03.016","article-title":"NMDA-receptor agonist reveals LTP-like properties of 10-Hz rTMS in the human motor cortex","volume":"14","author":"Brown","year":"2021","journal-title":"Brain Stimul"},{"issue":"6","key":"10.1053\/j.ackd.2021.10.008_bib40","doi-asserted-by":"crossref","first-page":"2201","DOI":"10.1046\/j.1523-1755.2002.00374.x","article-title":"Prevalence of renal cell carcinoma in patients with ESRD pre-transplantation: a pathologic analysis","volume":"61","author":"Denton","year":"2002","journal-title":"Kidney Int"},{"issue":"4","key":"10.1053\/j.ackd.2021.10.008_bib41","doi-asserted-by":"crossref","first-page":"750","DOI":"10.2215\/CJN.03661106","article-title":"Renal cell carcinoma in transplant recipients with acquired cystic kidney disease","volume":"2","author":"Schwarz","year":"2007","journal-title":"Clin J Am Soc Nephrol"},{"issue":"1","key":"10.1053\/j.ackd.2021.10.008_bib42","doi-asserted-by":"crossref","first-page":"86","DOI":"10.1111\/j.1600-6143.2010.03303.x","article-title":"Native renal cysts and dialysis duration are risk factors for renal cell carcinoma in renal transplant recipients","volume":"11","author":"Goh","year":"2011","journal-title":"Am J Transplant"},{"issue":"3","key":"10.1053\/j.ackd.2021.10.008_bib43","doi-asserted-by":"crossref","first-page":"667","DOI":"10.1148\/radiology.195.3.7753991","article-title":"Prevalence of acquired cystic kidney disease and tumors in native kidneys of renal transplant recipients: a prospective US study","volume":"195","author":"Heinz-Peer","year":"1995","journal-title":"Radiology"},{"issue":"12","key":"10.1053\/j.ackd.2021.10.008_bib44","doi-asserted-by":"crossref","first-page":"1951","DOI":"10.1681\/ASN.V4121951","article-title":"Renal cancer complicating acquired cystic kidney disease","volume":"4","author":"Marple","year":"1994","journal-title":"J Am Soc Nephrol"},{"issue":"1","key":"10.1053\/j.ackd.2021.10.008_bib45","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1016\/0272-6386(95)90146-9","article-title":"Renal neoplasm in acquired cystic kidney disease","volume":"26","author":"Truong","year":"1995","journal-title":"Am J Kidney Dis"},{"issue":"6","key":"10.1053\/j.ackd.2021.10.008_bib46","doi-asserted-by":"crossref","first-page":"1271","DOI":"10.1016\/j.urology.2011.01.007","article-title":"Incidence, predictors and associated outcomes of renal cell carcinoma in long-term dialysis patients","volume":"77","author":"Hurst","year":"2011","journal-title":"Urology"},{"issue":"9","key":"10.1053\/j.ackd.2021.10.008_bib47","doi-asserted-by":"crossref","first-page":"780","DOI":"10.1111\/iju.13759","article-title":"Renal tumors in end-stage renal disease: a comprehensive review","volume":"25","author":"Tsuzuki","year":"2018","journal-title":"Int J Urol"},{"issue":"1","key":"10.1053\/j.ackd.2021.10.008_bib48","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1007\/s00345-014-1248-y","article-title":"Clinical and pathological outcomes of renal cell carcinoma (RCC) in native kidneys of patients with end-stage renal disease: a long-term comparative retrospective study with RCC diagnosed in the general population","volume":"33","author":"Breda","year":"2015","journal-title":"World J Urol"},{"issue":"2","key":"10.1053\/j.ackd.2021.10.008_bib49","doi-asserted-by":"crossref","first-page":"211","DOI":"10.1111\/ctr.12299","article-title":"Renal cell carcinoma in patients with end-stage renal disease has favorable overall prognosis","volume":"28","author":"Shrewsberry","year":"2014","journal-title":"Clin Transplant"},{"issue":"12","key":"10.1053\/j.ackd.2021.10.008_bib50","doi-asserted-by":"crossref","first-page":"3479","DOI":"10.1111\/ajt.13862","article-title":"Risk of renal cell carcinoma among kidney transplant recipients in the United States","volume":"16","author":"Karami","year":"2016","journal-title":"Am J Transplant"},{"issue":"5","key":"10.1053\/j.ackd.2021.10.008_bib51","doi-asserted-by":"crossref","first-page":"376","DOI":"10.1097\/MOU.0b013e32834962bf","article-title":"Renal cell carcinoma of native kidneys in renal transplant patients","volume":"21","author":"Klatte","year":"2011","journal-title":"Curr Opin Urol"},{"issue":"8","key":"10.1053\/j.ackd.2021.10.008_bib52","doi-asserted-by":"crossref","first-page":"2457","DOI":"10.1093\/ndt\/gfn183","article-title":"Cancer in patients on dialysis and after renal transplantation","volume":"23","author":"Fischereder","year":"2008","journal-title":"Nephrol Dial Transpl"},{"issue":"23","key":"10.1053\/j.ackd.2021.10.008_bib53","doi-asserted-by":"crossref","first-page":"2823","DOI":"10.1001\/jama.296.23.2823","article-title":"Cancer incidence before and after kidney transplantation","volume":"296","author":"Vajdic","year":"2006","journal-title":"JAMA"},{"issue":"9","key":"10.1053\/j.ackd.2021.10.008_bib54","doi-asserted-by":"crossref","first-page":"735","DOI":"10.1016\/S1470-2045(06)70803-8","article-title":"Chronic kidney disease after nephrectomy in patients with renal cortical tumours: a retrospective cohort study","volume":"7","author":"Huang","year":"2006","journal-title":"Lancet Oncol"},{"issue":"4","key":"10.1053\/j.ackd.2021.10.008_bib55","doi-asserted-by":"crossref","first-page":"489","DOI":"10.1111\/j.1464-410X.2009.09147.x","article-title":"Predicting renal functional outcomes after surgery for renal cortical tumours: a multifactorial analysis","volume":"106","author":"Barlow","year":"2010","journal-title":"BJU Int"},{"issue":"4","key":"10.1053\/j.ackd.2021.10.008_bib56","doi-asserted-by":"crossref","first-page":"781","DOI":"10.1016\/j.urology.2010.11.050","article-title":"Prevalence of baseline chronic kidney disease in patients presenting with solid renal tumors","volume":"77","author":"Canter","year":"2011","journal-title":"Urology"},{"issue":"3","key":"10.1053\/j.ackd.2021.10.008_bib57","doi-asserted-by":"crossref","first-page":"658","DOI":"10.1016\/j.juro.2016.03.134","article-title":"Proteinuria is a predictor of renal functional decline in patients with kidney cancer","volume":"196","author":"O'Donnell","year":"2016","journal-title":"J Urol"},{"key":"10.1053\/j.ackd.2021.10.008_bib58","doi-asserted-by":"crossref","first-page":"101","DOI":"10.1016\/j.urology.2017.03.033","article-title":"Chronic kidney disease is more common in locally advanced renal cell carcinoma","volume":"105","author":"Dey","year":"2017","journal-title":"Urology"},{"issue":"3","key":"10.1053\/j.ackd.2021.10.008_bib59","doi-asserted-by":"crossref","first-page":"379","DOI":"10.1111\/j.1464-410X.2011.10331.x","article-title":"Tumour diameter and decreased preoperative estimated glomerular filtration rate are independently correlated in patients with renal cell carcinoma","volume":"109","author":"Donin","year":"2012","journal-title":"BJU Int"},{"issue":"4 Pt 1","key":"10.1053\/j.ackd.2021.10.008_bib60","doi-asserted-by":"crossref","first-page":"1135","DOI":"10.1097\/01.ju.0000085984.90991.9a","article-title":"Prognostic significance of albuminuria in patients with renal cell cancer","volume":"170","author":"Vaglio","year":"2003","journal-title":"J Urol"},{"issue":"11","key":"10.1053\/j.ackd.2021.10.008_bib61","doi-asserted-by":"crossref","first-page":"2127","DOI":"10.1007\/s11255-014-0780-4","article-title":"Renal insufficiency is associated with an increased risk of papillary renal cell carcinoma histology","volume":"46","author":"Woldu","year":"2014","journal-title":"Int Urol Nephrol"},{"issue":"6","key":"10.1053\/j.ackd.2021.10.008_bib62","doi-asserted-by":"crossref","first-page":"2363","DOI":"10.1016\/j.juro.2008.08.036","article-title":"Factors predicting renal functional outcome after partial nephrectomy","volume":"180","author":"Lane","year":"2008","journal-title":"J Urol"},{"issue":"1","key":"10.1053\/j.ackd.2021.10.008_bib63","doi-asserted-by":"crossref","first-page":"43","DOI":"10.1016\/j.juro.2010.09.019","article-title":"Chronic kidney disease before and after partial nephrectomy","volume":"185","author":"Clark","year":"2011","journal-title":"J Urol"},{"issue":"1","key":"10.1053\/j.ackd.2021.10.008_bib64","doi-asserted-by":"crossref","first-page":"64","DOI":"10.1016\/j.ejca.2013.08.018","article-title":"Small tumour size is associated with new-onset chronic kidney disease after radical nephrectomy in patients with renal cell carcinoma","volume":"50","author":"Jeon","year":"2014","journal-title":"Eur J Cancer"},{"issue":"4","key":"10.1053\/j.ackd.2021.10.008_bib65","doi-asserted-by":"crossref","first-page":"1242","DOI":"10.1016\/j.juro.2011.05.087","article-title":"Impact of tumor size on renal function and prediction of renal insufficiency after radical nephrectomy in patients with renal cell carcinoma","volume":"186","author":"Ohno","year":"2011","journal-title":"J Urol"},{"key":"10.1053\/j.ackd.2021.10.008_bib66","doi-asserted-by":"crossref","first-page":"333","DOI":"10.2147\/CLEP.S197968","article-title":"Tumor size and postoperative kidney function following radical nephrectomy","volume":"11","author":"Ellis","year":"2019","journal-title":"Clin Epidemiol"},{"issue":"2","key":"10.1053\/j.ackd.2021.10.008_bib67","doi-asserted-by":"crossref","first-page":"105","DOI":"10.1177\/23993693211031918","article-title":"Identifying patients with CKD risk at the time of nephrectomy: when to initiate nephrology consult","volume":"5","author":"Yang","year":"2021","journal-title":"J Onco-Nephrol"},{"issue":"11","key":"10.1053\/j.ackd.2021.10.008_bib68","doi-asserted-by":"crossref","first-page":"3496","DOI":"10.1093\/ndt\/gfr094","article-title":"Post-operative acute kidney injury in patients with renal cell carcinoma is a potent risk factor for new-onset chronic kidney disease after radical nephrectomy","volume":"26","author":"Cho","year":"2011","journal-title":"Nephrol Dial Transpl"},{"issue":"3","key":"10.1053\/j.ackd.2021.10.008_bib69","doi-asserted-by":"crossref","first-page":"398","DOI":"10.1016\/j.eururo.2019.04.040","article-title":"Impact of acute kidney injury and its duration on long-term renal function after partial nephrectomy","volume":"76","author":"Bravi","year":"2019","journal-title":"Eur Urol"},{"issue":"2","key":"10.1053\/j.ackd.2021.10.008_bib70","doi-asserted-by":"crossref","first-page":"405","DOI":"10.1016\/j.juro.2011.03.154","article-title":"Effect of parenchymal volume preservation on kidney function after partial nephrectomy","volume":"186","author":"Simmons","year":"2011","journal-title":"J Urol"},{"issue":"2","key":"10.1053\/j.ackd.2021.10.008_bib71","doi-asserted-by":"crossref","first-page":"421","DOI":"10.1016\/j.juro.2010.09.131","article-title":"Comparison of cold and warm ischemia during partial nephrectomy in 660 solitary kidneys reveals predominant role of nonmodifiable factors in determining ultimate renal function","volume":"185","author":"Lane","year":"2011","journal-title":"J Urol"},{"issue":"6","key":"10.1053\/j.ackd.2021.10.008_bib72","doi-asserted-by":"crossref","first-page":"1655","DOI":"10.1016\/j.juro.2015.09.099","article-title":"Current paradigm for ischemia in kidney surgery","volume":"195","author":"Mir","year":"2016","journal-title":"J Urol"},{"issue":"4","key":"10.1053\/j.ackd.2021.10.008_bib73","doi-asserted-by":"crossref","first-page":"1284","DOI":"10.1016\/j.juro.2007.11.071","article-title":"Correlation between loss of renal function and loss of renal volume after partial nephrectomy for tumor in a solitary kidney","volume":"179","author":"Sharma","year":"2008","journal-title":"J Urol"},{"issue":"5","key":"10.1053\/j.ackd.2021.10.008_bib74","doi-asserted-by":"crossref","first-page":"904","DOI":"10.1016\/j.urology.2004.07.006","article-title":"Prediction of postoperative renal function by preoperative serum creatinine level and three-dimensional diagnostic image reconstruction in patients with renal cell carcinoma","volume":"64","author":"Tanaka","year":"2004","journal-title":"Urology"},{"issue":"6","key":"10.1053\/j.ackd.2021.10.008_bib75","doi-asserted-by":"crossref","first-page":"1889","DOI":"10.1016\/j.juro.2015.01.093","article-title":"Decline in renal function after partial nephrectomy: etiology and prevention","volume":"193","author":"Mir","year":"2015","journal-title":"J Urol"},{"issue":"6","key":"10.1053\/j.ackd.2021.10.008_bib76","doi-asserted-by":"crossref","first-page":"1612","DOI":"10.1016\/j.juro.2014.06.018","article-title":"Compensatory hypertrophy after partial and radical nephrectomy in adults","volume":"192","author":"Takagi","year":"2014","journal-title":"J Urol"},{"issue":"4","key":"10.1053\/j.ackd.2021.10.008_bib77","doi-asserted-by":"crossref","first-page":"910","DOI":"10.1016\/j.juro.2015.04.093","article-title":"Compensatory structural and functional adaptation after radical nephrectomy for renal cell carcinoma according to preoperative stage of chronic kidney disease","volume":"194","author":"Choi","year":"2015","journal-title":"J Urol"},{"issue":"9","key":"10.1053\/j.ackd.2021.10.008_bib78","doi-asserted-by":"crossref","first-page":"1205","DOI":"10.1016\/j.ekir.2019.07.001","article-title":"Current management of patients with acquired solitary kidney","volume":"4","author":"Tantisattamo","year":"2019","journal-title":"Kidney Int Rep"},{"issue":"15","key":"10.1053\/j.ackd.2021.10.008_bib79","doi-asserted-by":"crossref","first-page":"1058","DOI":"10.1056\/NEJM199110103251502","article-title":"Long-term follow-up after partial removal of a solitary kidney","volume":"325","author":"Novick","year":"1991","journal-title":"N Engl J Med"},{"issue":"5","key":"10.1053\/j.ackd.2021.10.008_bib80","doi-asserted-by":"crossref","first-page":"1649","DOI":"10.1016\/j.juro.2012.11.121","article-title":"Surgically induced chronic kidney disease may be associated with a lower risk of progression and mortality than medical chronic kidney disease","volume":"189","author":"Lane","year":"2013","journal-title":"J Urol"},{"issue":"4","key":"10.1053\/j.ackd.2021.10.008_bib81","doi-asserted-by":"crossref","first-page":"1057","DOI":"10.1016\/j.juro.2014.04.016","article-title":"Chronic kidney disease due to surgical removal of nephrons: relative rates of progression and survival","volume":"192","author":"Demirjian","year":"2014","journal-title":"J Urol"},{"issue":"2","key":"10.1053\/j.ackd.2021.10.008_bib82","doi-asserted-by":"crossref","first-page":"231","DOI":"10.1097\/JU.0000000000001005","article-title":"The urine albumin-to-creatinine ratio and kidney function after nephrectomy","volume":"204","author":"Sun","year":"2020","journal-title":"J Urol"},{"issue":"3","key":"10.1053\/j.ackd.2021.10.008_bib83","doi-asserted-by":"crossref","first-page":"588","DOI":"10.1016\/j.juro.2015.09.083","article-title":"Impact of reduced glomerular filtration rate and proteinuria on overall survival of patients with renal cancer","volume":"195","author":"Tourojman","year":"2016","journal-title":"J Urol"},{"issue":"6","key":"10.1053\/j.ackd.2021.10.008_bib84","doi-asserted-by":"crossref","first-page":"409","DOI":"10.4111\/icu.2017.58.6.409","article-title":"Impact of preoperative proteinuria on renal functional outcomes after open partial nephrectomy in patients with a solitary kidney","volume":"58","author":"Tachibana","year":"2017","journal-title":"Investig Clin Urol"},{"issue":"5","key":"10.1053\/j.ackd.2021.10.008_bib85","doi-asserted-by":"crossref","first-page":"706","DOI":"10.1093\/annonc\/mdz056","article-title":"Renal cell carcinoma: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-updagger","volume":"30","author":"Escudier","year":"2019","journal-title":"Ann Oncol"},{"issue":"1","key":"10.1053\/j.ackd.2021.10.008_bib86","doi-asserted-by":"crossref","first-page":"108","DOI":"10.1093\/ndt\/gfy105","article-title":"Programmed cell death protein 1 inhibitor treatment is associated with acute kidney injury and hypocalcemia: meta-analysis","volume":"34","author":"Manohar","year":"2019","journal-title":"Nephrol Dial Transpl"},{"issue":"3","key":"10.1053\/j.ackd.2021.10.008_bib87","doi-asserted-by":"crossref","first-page":"638","DOI":"10.1016\/j.kint.2016.04.008","article-title":"Clinicopathological features of acute kidney injury associated with immune checkpoint inhibitors","volume":"90","author":"Cortazar","year":"2016","journal-title":"Kidney Int"},{"issue":"12","key":"10.1053\/j.ackd.2021.10.008_bib88","doi-asserted-by":"crossref","first-page":"1103","DOI":"10.1056\/NEJMoa1816047","article-title":"Avelumab plus axitinib versus sunitinib for advanced renal-cell carcinoma","volume":"380","author":"Motzer","year":"2019","journal-title":"N Engl J Med"},{"issue":"12","key":"10.1053\/j.ackd.2021.10.008_bib89","doi-asserted-by":"crossref","first-page":"1563","DOI":"10.1016\/S1470-2045(20)30436-8","article-title":"Pembrolizumab plus axitinib versus sunitinib monotherapy as first-line treatment of advanced renal cell carcinoma (KEYNOTE-426): extended follow-up from a randomised, open-label, phase 3 trial","volume":"21","author":"Powles","year":"2020","journal-title":"Lancet Oncol"},{"issue":"6","key":"10.1053\/j.ackd.2021.10.008_bib90","doi-asserted-by":"crossref","first-page":"723","DOI":"10.1007\/s00280-021-04260-y","article-title":"Renal toxicity of targeted therapies for renal cell carcinoma in patients with normal and impaired kidney function","volume":"87","author":"Mielczarek","year":"2021","journal-title":"Cancer Chemother Pharmacol"},{"issue":"1","key":"10.1053\/j.ackd.2021.10.008_bib91","doi-asserted-by":"crossref","first-page":"109","DOI":"10.1186\/s40425-018-0420-0","article-title":"Safety and efficacy of nivolumab in combination with sunitinib or pazopanib in advanced or metastatic renal cell carcinoma: the CheckMate 016 study","volume":"6","author":"Amin","year":"2018","journal-title":"J Immunother Cancer"},{"issue":"1","key":"10.1053\/j.ackd.2021.10.008_bib92","doi-asserted-by":"crossref","first-page":"62","DOI":"10.1016\/j.kint.2019.07.022","article-title":"Immune checkpoint inhibitor nephrotoxicity: what do we know and what should we do?","volume":"97","author":"Perazella","year":"2020","journal-title":"Kidney Int"},{"issue":"2","key":"10.1053\/j.ackd.2021.10.008_bib93","doi-asserted-by":"crossref","first-page":"435","DOI":"10.1681\/ASN.2019070676","article-title":"Clinical features and outcomes of immune checkpoint inhibitor-associated AKI: a multicenter study","volume":"31","author":"Cortazar","year":"2020","journal-title":"J Am Soc Nephrol"},{"issue":"1","key":"10.1053\/j.ackd.2021.10.008_bib94","doi-asserted-by":"crossref","first-page":"2","DOI":"10.1186\/s40425-018-0478-8","article-title":"Nephrotoxicity of immune checkpoint inhibitors beyond tubulointerstitial nephritis: single-center experience","volume":"7","author":"Mamlouk","year":"2019","journal-title":"J Immunother Cancer"},{"issue":"1","key":"10.1053\/j.ackd.2021.10.008_bib95","doi-asserted-by":"crossref","first-page":"66","DOI":"10.1016\/j.ekir.2020.10.002","article-title":"A systematic review of immune checkpoint inhibitor-associated glomerular disease","volume":"6","author":"Kitchlu","year":"2021","journal-title":"Kidney Int Rep"},{"issue":"2","key":"10.1053\/j.ackd.2021.10.008_bib96","doi-asserted-by":"crossref","first-page":"e000213","DOI":"10.1136\/esmoopen-2017-000213","article-title":"Mechanisms of action and rationale for the use of checkpoint inhibitors in cancer","volume":"2","author":"Granier","year":"2017","journal-title":"ESMO Open"},{"issue":"9807","key":"10.1053\/j.ackd.2021.10.008_bib97","doi-asserted-by":"crossref","first-page":"1931","DOI":"10.1016\/S0140-6736(11)61613-9","article-title":"Comparative effectiveness of axitinib versus sorafenib in advanced renal cell carcinoma (AXIS): a randomised phase 3 trial","volume":"378","author":"Rini","year":"2011","journal-title":"Lancet"},{"issue":"8","key":"10.1053\/j.ackd.2021.10.008_bib98","doi-asserted-by":"crossref","first-page":"722","DOI":"10.1056\/NEJMoa1303989","article-title":"Pazopanib versus sunitinib in metastatic renal-cell carcinoma","volume":"369","author":"Motzer","year":"2013","journal-title":"N Engl J Med"},{"key":"10.1053\/j.ackd.2021.10.008_bib99","doi-asserted-by":"crossref","first-page":"115","DOI":"10.1016\/j.ejca.2018.02.012","article-title":"Cabozantinib versus sunitinib as initial therapy for metastatic renal cell carcinoma of intermediate or poor risk (Alliance A031203 CABOSUN randomised trial): progression-free survival by independent review and overall survival update","volume":"94","author":"Choueiri","year":"2018","journal-title":"Eur J Cancer"},{"issue":"5","key":"10.1053\/j.ackd.2021.10.008_bib100","doi-asserted-by":"crossref","first-page":"427","DOI":"10.1056\/NEJMoa021491","article-title":"A randomized trial of bevacizumab, an anti-vascular endothelial growth factor antibody, for metastatic renal cancer","volume":"349","author":"Yang","year":"2003","journal-title":"N Engl J Med"},{"issue":"11","key":"10.1053\/j.ackd.2021.10.008_bib101","doi-asserted-by":"crossref","first-page":"975","DOI":"10.1016\/S1470-2045(07)70285-1","article-title":"Axitinib treatment in patients with cytokine-refractory metastatic renal-cell cancer: a phase II study","volume":"8","author":"Rixe","year":"2007","journal-title":"Lancet Oncol"},{"issue":"9","key":"10.1053\/j.ackd.2021.10.008_bib102","doi-asserted-by":"crossref","first-page":"1918","DOI":"10.1016\/j.humpath.2014.05.015","article-title":"Clinicopathological spectrum of kidney diseases in cancer patients treated with vascular endothelial growth factor inhibitors: a report of 5 cases and review of literature","volume":"45","author":"Usui","year":"2014","journal-title":"Hum Pathol"},{"issue":"5","key":"10.1053\/j.ackd.2021.10.008_bib103","doi-asserted-by":"crossref","first-page":"1742","DOI":"10.1093\/ndt\/gfr093","article-title":"Crescentic glomerulonephritis associated with vascular endothelial growth factor (VEGF) inhibitor and bisphosphonate administration","volume":"26","author":"Stylianou","year":"2011","journal-title":"Nephrol Dial Transpl"},{"issue":"6","key":"10.1053\/j.ackd.2021.10.008_bib104","doi-asserted-by":"crossref","first-page":"2002","DOI":"10.1093\/ndt\/gfp140","article-title":"Acute nephritic syndrome after anti-VEGF therapy for renal cell carcinoma","volume":"24","author":"Rolleman","year":"2009","journal-title":"Nephrol Dial Transpl"},{"issue":"12","key":"10.1053\/j.ackd.2021.10.008_bib105","doi-asserted-by":"crossref","first-page":"1313","DOI":"10.1038\/bjc.2016.147","article-title":"Risk factors of proteinuria in renal cell carcinoma patients treated with VEGF inhibitors: a secondary analysis of pooled clinical trial data","volume":"114","author":"Sorich","year":"2016","journal-title":"Br J Cancer"},{"issue":"1","key":"10.1053\/j.ackd.2021.10.008_bib106","doi-asserted-by":"crossref","first-page":"31","DOI":"10.2217\/fon-2016-0355","article-title":"Long-term response to sunitinib: everolimus treatment in metastatic clear cell renal cell carcinoma","volume":"13","author":"Czarnecka","year":"2017","journal-title":"Future Oncol"},{"issue":"2","key":"10.1053\/j.ackd.2021.10.008_bib107","doi-asserted-by":"crossref","first-page":"455","DOI":"10.4081\/oncol.2019.455","article-title":"Renal toxicity with mammalian target of rapamycin inhibitors: a meta-analysis of randomized clinical trials","volume":"13","author":"Paluri","year":"2019","journal-title":"Oncol Rev"},{"issue":"4","key":"10.1053\/j.ackd.2021.10.008_bib108","doi-asserted-by":"crossref","first-page":"1216","DOI":"10.1016\/j.transproceed.2009.03.093","article-title":"Posttransplant proteinuria associated with everolimus","volume":"41","author":"Bertoni","year":"2009","journal-title":"Transplant Proc"},{"issue":"1-3","key":"10.1053\/j.ackd.2021.10.008_bib109","doi-asserted-by":"crossref","first-page":"143","DOI":"10.1016\/j.ejphar.2012.09.010","article-title":"Involvement of autophagy in the pharmacological effects of the mTOR inhibitor everolimus in acute kidney injury","volume":"696","author":"Nakagawa","year":"2012","journal-title":"Eur J Pharmacol"},{"issue":"9","key":"10.1053\/j.ackd.2021.10.008_bib110","doi-asserted-by":"crossref","first-page":"2421","DOI":"10.1093\/annonc\/mdt233","article-title":"Acute tubular necrosis associated with mTOR inhibitor therapy: a real entity biopsy-proven","volume":"24","author":"Izzedine","year":"2013","journal-title":"Ann Oncol"},{"issue":"8","key":"10.1053\/j.ackd.2021.10.008_bib111","doi-asserted-by":"crossref","first-page":"e52","DOI":"10.1097\/MD.0000000000000052","article-title":"Increased risk of end-stage renal disease in patients with renal cell carcinoma: a 12-year nationwide follow-up study","volume":"93","author":"Hung","year":"2014","journal-title":"Medicine (Baltimore)"},{"issue":"1","key":"10.1053\/j.ackd.2021.10.008_bib112","doi-asserted-by":"crossref","first-page":"247","DOI":"10.1046\/j.1523-1755.2003.00060.x","article-title":"Renal cell carcinoma as a cause of end-stage renal disease in the United States: patient characteristics and survival","volume":"64","author":"Stiles","year":"2003","journal-title":"Kidney Int"},{"issue":"9","key":"10.1053\/j.ackd.2021.10.008_bib113","doi-asserted-by":"crossref","first-page":"2012","DOI":"10.1093\/ckj\/sfab090","article-title":"Immune checkpoint inhibitor use in patients with end-stage kidney disease: an analysis of reported cases and literature review","volume":"14","author":"Kitchlu","year":"2021","journal-title":"Clin Kidney J"},{"issue":"8","key":"10.1053\/j.ackd.2021.10.008_bib114","doi-asserted-by":"crossref","first-page":"1279","DOI":"10.1111\/j.1464-410X.2010.09990.x","article-title":"Efficacy and toxicity of sunitinib in patients with metastatic renal cell carcinoma with severe renal impairment or on haemodialysis","volume":"108","author":"Josephs","year":"2011","journal-title":"BJU Int"},{"issue":"11","key":"10.1053\/j.ackd.2021.10.008_bib115","doi-asserted-by":"crossref","first-page":"1081","DOI":"10.1111\/iju.14093","article-title":"Efficacy and safety of axitinib for metastatic renal cell carcinoma in patients on hemodialysis for end-stage renal disease: case series of eight patients","volume":"26","author":"Ishihara","year":"2019","journal-title":"Int J Urol"}],"container-title":["Advances in Chronic Kidney Disease"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1548559521001294?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1548559521001294?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,10,27]],"date-time":"2025-10-27T07:04:44Z","timestamp":1761548684000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S1548559521001294"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2021,9]]},"references-count":115,"journal-issue":{"issue":"5","published-print":{"date-parts":[[2021,9]]}},"alternative-id":["S1548559521001294"],"URL":"https:\/\/doi.org\/10.1053\/j.ackd.2021.10.008","relation":{},"ISSN":["1548-5595"],"issn-type":[{"value":"1548-5595","type":"print"}],"subject":[],"published":{"date-parts":[[2021,9]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Renal Cell Cancer and Chronic Kidney Disease","name":"articletitle","label":"Article Title"},{"value":"Advances in Chronic Kidney Disease","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1053\/j.ackd.2021.10.008","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2021 by the National Kidney Foundation, Inc. All rights reserved.","name":"copyright","label":"Copyright"}]}}